, Tracking Stock Market Picks
Enter Symbol:
Allos Therapeutics, Inc. (ALTH) [hlAlert]

down 68.16 %

Allos Therapeutics, Inc. (ALTH) rated Buy with price target $9 by Collins Stewart

Posted on: Thursday,  Feb 28, 2008  11:25 AM ET by Collins Stewart

Collins Stewart rated Buy Allos Therapeutics, Inc. (NASDAQ: ALTH) on 02/28/2008. Previously Collins Stewart rated Buy Allos Therapeutics, Inc. (NASDAQ: ALTH) on
11/08/2007., when the stock price was $5.78. Since then, Allos Therapeutics, Inc. has lost 68.17% as of 09/05/2012's recent price of $1.84.
If you would have followed the previous Collins Stewart's recommendation on ALTH, you would have lost 68.16% of your investment in 1763 days.

Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs, initially for improving cancer treatments. The company's lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells.

Collins Stewart's research department is built around a number of sector-specialist teams. Our analysts are leaders in their area of specialisation and combine deep industry knowledge with decades of stock broking experience to produce insightful, independent sector research. Our research approach encompasses Questâ„¢ principles and focuses on cash-driven valuation techniques. Research is a Collins Stewart cornerstone; it is leveraged throughout the organisation.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/28/2008 11:25 AM Buy
5.76 9.00
as of 12/24/2008
1 Week down  -1.37 %
1 Month down  -11.94 %
3 Months down  -19.46 %
1 YTD down  -6.04 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/8/2007 11:25 AM Buy
5.78 23.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy